Pharmacokinetic and biodistribution studies of doxorubicin-loaded single-wall carbon nanohorns in mice
Source abstract
Abstract
Pharmacokinetic and biodistribution studies of doxorubicin-loaded carbon nanohorns (DOX@oxSWCNHs/SA) in plasma and tissues were carried out. A high-performance liquid chromatographic method was developed and validated to determine the amount of doxorubicin. Compared with free DOX, the half-life (t 1/2) of DOX@oxSWCNHs/SA was increased from 5.44 ± 1.09 to 7.38 ± 0.98 h, area under plasma concentration–time curve (AUC0–∞) was increased from 0.63 ± 0.008 to 1.42 ± 0.12 μg/(ml h), and the clearance of DOX was declined from 634 ± 10.05 to 280 ± 24.06 ml/h. No DOX was detected in heart after intravenous injection with DOX@oxSWCNHs/SA, while higher concentrations of drug were found in other tissues. These results suggested that DOX@oxSWCNHs/SA had the potential to obtain a long retention time in blood, sustained drug release, and a low toxicity, especially low cardiotoxicity.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · Carbon Nanotubes in Composites · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Ajima K, Yudasaka M, Murakami T, Maigné A, Shiba K, Iijima S (2005) Carbon nanohorns as anticancer drug carriers. Mol Pharm 2(6):475–48010.1021/mp0500566 ↗
2. Alhareth K, Vauthier C, Bourasset F, Gueutin C, Ponchel G, Moussa F (2012a) Conformation of surface-decorating dextran chains affects the pharmacokinetics and biodistribution of doxorubicin-loaded nanoparticles. Eur J Pharm Biopharm 81(2):453–45710.1016/j.ejpb.2012.03.009 ↗
3. Alhareth K, Vauthier C, Gueutin C, Ponchel G, Moussa F (2012b) HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly (alkylcyanoacrylate) nanoparticles. J Chromatogr B 887:128–13210.1016/j.jchromb.2012.01.025 ↗
4. Al-Jamal KT, Nunes A, Methven L, Ali-Boucetta H, Li S, Toma FM, Herrero MA, Al-Jamal WT, ten Eikelder HM, Foster J (2012) Degree of chemical functionalization of carbon nanotubes determines tissue distribution and excretion profile. Angew Chem Int Edit 51(26):6389–639310.1002/anie.201201991 ↗
5. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1. Annu Rev Pharmacol Toxicol 39(1):361–39810.1146/annurev.pharmtox.39.1.361 ↗
6. AssumpçãO JUCV, Campos ML, Nogueira Filho F, Antonio M, Pestana KC, Baldan HM, Formariz Pilon TP, de Oliveira AG, Peccinini RG (2013) Biocompatible microemulsion modifies the pharmacokinetic profile and cardiotoxicity of doxorubicin. J Pharm Sci 102(1):289–29610.1002/jps.23368 ↗
7. Barpe DR, Rosa DD, Froehlich PE (2010) Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci 41(3):458–46310.1016/j.ejps.2010.07.015 ↗
8. Bekyarova E, Kaneko K, Kasuya D, Murata K, Yudasaka M, Iijima S (2002) Oxidation and porosity evaluation of budlike single-wall carbon nanohorn aggregates. Langmuir 18(10):4138–414110.1021/la0117348 ↗
9. Bekyarova E, Kaneko K, Yudasaka M, Kasuya D, Iijima S, Huidobro A, Rodriguez-Reinoso F (2003) Controlled opening of single-wall carbon nanohorns by heat treatment in carbon dioxide. J Phys Chem B 107(19):4479–448410.1021/jp026737n ↗
10. Booser DJ, Hortobagyi GN (1994) Anthracycline antibiotics in cancer therapy. Drugs 47(2):223–25810.2165/00003495-199447020-00002 ↗
11. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI (2009) Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16(25):3267–328510.2174/092986709788803312 ↗
12. Charrois GJ, Allen TM (2004) Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. BBA-Biomembranes 1663(1):167–17710.1016/j.bbamem.2004.03.006 ↗
13. Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R (2008) An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 61(4):695–70210.1007/s00280-007-0525-5 ↗
14. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312–332210.1200/JCO.2001.19.14.3312 ↗
15. Heldin C-H, Rubin K, Pietras K, Östman A (2004) High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer 4(10):806–81310.1038/nrc1456 ↗
16. Horie M, Komaba LK, Fukui H, Kato H, Endoh S, Nakamura A, Miyauchi A, Maru J, Miyako E, Fujita K (2013) Evaluation of the biological influence of a stable carbon nanohorn dispersion. Carbon 54:155–16710.1016/j.carbon.2012.11.015 ↗
17. Hu T, Le Q, Wu Z, Wu W (2007) Determination of doxorubicin in rabbit ocular tissues and pharmacokinetics after intravitreal injection of a single dose of doxorubicin-loaded poly-β-hydroxybutyrate microspheres. J Pharm Biomed Anal 43(1):263–26910.1016/j.jpba.2006.06.032 ↗
18. Huang W, Zhang J, Dorn HC, Zhang C (2013) Assembly of bio-nanoparticles for double controlled drug release. PLoS One 8(9):e7467910.1371/journal.pone.0074679 ↗
19. Iijima S, Yudasaka M, Yamada R, Bandow S, Suenaga K, Kokai F, Takahashi K (1999) Nano-aggregates of single-walled graphitic carbon nano-horns. Chem Phys Lett 309(3):165–17010.1016/S0009-2614(99)00642-9 ↗
20. Iwamoto T (2013) Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol Pharm Bull 36(5):715–71810.1248/bpb.b12-01102 ↗
21. Jain D (2000) Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 7(1):53–6210.1067/mnc.2000.103324 ↗
22. Kümmerle A, Krueger T, Dusmet M, Vallet C, Pan Y, Ris H, Decosterd LA (2003) A validated assay for measuring doxorubicin in biological fluids and tissues in an isolated lung perfusion model: matrix effect and heparin interference strongly influence doxorubicin measurements. J Pharm Biomed 33(3):475–49410.1016/S0731-7085(03)00300-5 ↗
23. Laginha KM, Verwoert S, Charrois GJ, Allen TM (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 11(19):6944–694910.1158/1078-0432.CCR-05-0343 ↗
24. Li N, Zhao Q, Shu C, Ma X, Li R, Shen H, Zhong W (2015) Targeted killing of cancer cells in vivo and in vitro with IGF-IR antibody-directed carbon nanohorns based drug delivery. Int J Pharm 478(2):644–65410.1016/j.ijpharm.2014.12.015 ↗
25. Lin J, Shigdar S, Fang DZ, Xiang D, Wei MQ, Danks A, Kong L, Li L, Qiao L, Duan W (2014) Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model. PLoS One 9(7):1–13
26. Liu Z, Davis C, Cai W, He L, Chen X, Dai H (2008) Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci USA 105(5):1410–141510.1073/pnas.0707654105 ↗
27. Liu Z, Fan AC, Rakhra K, Sherlock S, Goodwin A, Chen X, Yang Q, Felsher DW, Dai H (2009) Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Edit 48(41):7668–767210.1002/anie.200902612 ↗
28. Liu H, Xu H, Wang Y, He Z, Li S (2012) Effect of intratumoral injection on the biodistribution and therapeutic potential of novel chemophor EL-modified single-walled nanotube loading doxorubicin. Drug Dev Ind Pharm 38(9):1031–103810.3109/03639045.2011.637050 ↗
29. Ma X, Shu C, Guo J, Pang L, Su L, Fu D, Zhong W (2014) Targeted cancer therapy based on single-wall carbon nanohorns with doxorubicin in vitro and in vivo. J Nanopart Res 16(7):1–14
30. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65(1):271–28410.1016/S0168-3659(99)00248-5 ↗
31. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46(12 Part 1):6387–6392
32. Miyawaki J, Yudasaka M, Azami T, Kubo Y, Iijima S (2008) Toxicity of single-walled carbon nanohorns. ACS Nano 2(2):213–22610.1021/nn700185t ↗
33. Miyawaki J, Matsumura S, Yuge R, Murakami T, Sato S, Tomida A, Tsuruo T, Ichihashi T, Fujinami T, Irie H (2009) Biodistribution and ultrastructural localization of single-walled carbon nanohorns determined in vivo with embedded Gd2O3 labels. ACS Nano 3(6):1399–140610.1021/nn9004846 ↗
34. Murakami T, Sawada H, Tamura G, Yudasaka M, Iijima S, Tsuchida K (2008) Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy. Nanomedicine 3(4):453–46310.2217/17435889.3.4.453 ↗
35. Murata K, Kaneko K, Steele W, Kokai F, Takahashi K, Kasuya D, Yudasaka M, Iijima S (2001) Porosity evaluation of intrinsic intraparticle nanopores of single wall carbon nanohorn. Nano Lett 1(4):197–19910.1021/nl015509m ↗
36. Nakamura M, Tahara Y, Ikehara Y, Murakami T, Tsuchida K, Iijima S, Waga I, Yudasaka M (2011) Single-walled carbon nanohorns as drug carriers: adsorption of prednisolone and anti-inflammatory effects on arthritis. Nanotechnology 22(46):46510210.1088/0957-4484/22/46/465102 ↗
37. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52(6):1213–122510.1016/j.yjmcc.2012.03.006 ↗
38. Ogura M (2001) Adriamycin (doxorubicin). Gan to kagaku ryoho Cancer Chemother 28(10):1331–1338
39. Patel NR, Pattni BS, Abouzeid AH, Torchilin VP (2013) Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev 65(13):1748–176210.1016/j.addr.2013.08.004 ↗
40. Sharma R, Tobin P, Clarke SJ (2005) Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6(2):93–10210.1016/S1470-2045(05)01735-3 ↗
41. Tahara Y, Miyawaki J, Zhang M, Yang M, Waga I, Iijima S, Irie H, Yudasaka M (2011) Histological assessments for toxicity and functionalization-dependent biodistribution of carbon nanohorns. Nanotechnology 22(26):265106–26511310.1088/0957-4484/22/26/265106 ↗
42. Urva SR, Shin BS, Yang VC, Balthasar JP (2009) Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. J Chromatogr B 877(8):837–84110.1016/j.jchromb.2009.02.018 ↗
43. Wang J, Hu Z, Xu J, Zhao Y (2014) Therapeutic applications of low-toxicity spherical nanocarbon materials. NPG Asia Mater 6(2):e8410.1038/am.2013.79 ↗
44. Waterhouse DN, Tardi PG, Mayer LD, Bally MB (2001) A comparison of liposomal formulations of doxorubicin with drug administered in free form. Drug Saf 24(12):903–92010.2165/00002018-200124120-00004 ↗
45. Wu W, Li R, Bian X, Zhu Z, Ding D, Li X, Jia Z, Jiang X, Hu Y (2009) Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity. ACS Nano 3(9):2740–275010.1021/nn9005686 ↗
46. Yamashita T, Yamashita K, Nabeshi H, Yoshikawa T, Yoshioka Y, S-i Tsunoda, Tsutsumi Y (2012) Carbon nanomaterials: efficacy and safety for nanomedicine. Materials 5(2):350–36310.3390/ma5020350 ↗
47. Yang S-t, Guo W, Lin Y, Deng X-y, Wang H-f, Sun H-f, Liu Y-f, Wang X, Wang W, Chen M (2007) Biodistribution of pristine single-walled carbon nanotubes in vivo. J Phys Chem C 111(48):17761–1776410.1021/jp070712c ↗
48. Zamboni WC (2005) Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 11(23):8230–823410.1158/1078-0432.CCR-05-1895 ↗
49. Zamboni WC (2008) Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 13(3):248–26010.1634/theoncologist.2007-0180 ↗
50. Zhang Y, Huo M, Zhou J, Xie S (2010) PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99(3):306–31410.1016/j.cmpb.2010.01.007 ↗
51. Zhang M, Yamaguchi T, Iijima S, Yudasaka M (2013) Size-dependent biodistribution of carbon nanohorns in vivo. Nanomed-Nanotechnol 9(5):657–66410.1016/j.nano.2012.11.011 ↗
52. Zhang M, Tahara Y, Yang M, Zhou X, Iijima S, Yudasaka M (2014) Quantification of whole body and excreted carbon nanohorns intravenously injected into mice. Adv Healthc Mater 3(2):239–24410.1002/adhm.201300192 ↗